SCHEMBL4570056

SCHEMBL4570056

CCCOC(=O)Nc1ccc(N2CCC[C@]3(CCN(c4ccccc4Cl)C3=O)C2)nc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.41
TP53 P04637 2/20 0.41
HPGD P15428 1/20 0.41
CRBN Q96SW2 2/20 0.41
TRPV1 Q8NER1 1/20 0.38
RAB9A P51151 3/20 0.37
ALDH1A1 P00352 1/20 0.37
TSHR P16473 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
POLB P06746 1/20 0.36
MAPT P10636 2/20 0.36
KMT2A Q03164 2/20 0.36
NPY5R Q15761 1/20 0.36
NPC1 O15118 1/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
LMNA P02545 3/20 0.35
DGAT1 O75907 2/20 0.35
KCNQ2 O43526 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17082004 1.00 SMN1; SMN2 (0.41) SMN1; SMN2TP53HPGDCRBNTRPV1
SCHEMBL4570055 0.94 CRBN (0.42) CRBNTRPV1RAB9AALDH1A1TSHR
SCHEMBL17082015 0.94 CRBN (0.42) CRBNTRPV1RAB9AALDH1A1TSHR
SCHEMBL4570054 0.90 CRBN (0.44) SMN1; SMN2HPGDCRBNTRPV1RAB9A
SCHEMBL17082048 0.90 CRBN (0.44) SMN1; SMN2HPGDCRBNTRPV1RAB9A
SCHEMBL2701119 0.86 CRBN (0.44) SMN1; SMN2CRBNRAB9APOLBMAPT
SCHEMBL5930600 0.86 CRBN (0.44) SMN1; SMN2CRBNRAB9APOLBMAPT
SCHEMBL3700460 0.86 CRBN (0.44) SMN1; SMN2CRBNRAB9APOLBMAPT
SCHEMBL17082171 0.80 CRBN (0.44) SMN1; SMN2TP53HPGDCRBNTRPV1
SCHEMBL4570144 0.80 CRBN (0.44) SMN1; SMN2TP53HPGDCRBNTRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122858-A1 LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2012-05-17 US disclosed
US-20120122858-A1 LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2012-05-17 US disclosed
US-8110581-B2 Lactam compounds and their use as pharmaceuticals INCYTE CORPORATION (US) 2012-02-07 US disclosed
US-8110581-B2 Lactam compounds and their use as pharmaceuticals INCYTE CORPORATION (US) 2012-02-07 US disclosed
US-20090291946-A1 LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2009-11-26 US disclosed
US-20090291946-A1 LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2009-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291946-A1 LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS HSD11B1, HSD11B2, HSD17B1 SMN1; SMN2 3517/4885TP53 4797/4885HPGD 45/4885
US-20120122858-A1 LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS HSD11B1, HSD11B2, HSD17B1 SMN1; SMN2 3517/4885TP53 4797/4885HPGD 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.